Militarized youths in western Côte d’Ivoire: local processes of mobilization, demobilization, and related humanitarian interventions (2002-2007) - Cover

In the small number of PALB2 associated breast tumours that have been analyzed so far, no loss of the wild type PALB2 allele could be detected (Erkko et al., 2007; Tischkowitz et al.,

We show that secondary mutations in the Brca1 gene are not always required to develop resistance to platinum drugs or PARP inhibitors, as residual activity of BRCA1 mutant

Since KB1(185stop)P mouse mammary tumors have a poor response to olaparib and cisplatin compared to KB1(5382stop)P and BRCA1-deficient KB1P tumors, we studied

While platinum agents and PARP inhibitors have been shown to be effective in the treatment of BRCA1/2- mutated cancer in the clinic, the presence of a BRCA1/2 mutation is not always

We have introduced the C61G mutation into a conditional mouse model for BRCA1-related breast cancer in order to unravel the function of the BRCA1 RING domain in tumor suppression

Om de functie van het BRCA1 RING domein in tumorsuppressie en therapierespons te kunnen ontrafelen, hebben wij de C61G mutatie geïntroduceerd in een conditioneel

Subsequently, she performed a 6-month internship at the division of Molecular Biology of the Netherlands Cancer Institute in the group of Dr. Jos Jonkers, under

Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S, Klijn C, van der Heijden I, van der Gulden H, Wientjens E, Pieterse M, Catteau A, Green P, Solomon E, Morris JR,